Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: A concise overview

Advanced Drug Delivery Reviews

Volumn 65, Issue 10, 2013, Pages 1316-1330

  Mignani, Serge ^a   El Kazzouli, Saïd ^b   Bousmina, Mosto ^c   Majoral, Jean Pierre ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b MOHAMMED V UNIVERSITY   (Morocco)

^c HASSAN II ACADEMY OF SCIENCE AND TECHNOLOGY   (Morocco)

^d LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

Author keywords

Dendrimers; Inhalation administration; Intravenous route; Nasal administration; Ocular drug delivery; Oral route; Routes of administration; Transdermal diffusion

Indexed keywords

INTRAVENOUS ROUTE; NASAL ADMINISTRATION; OCULAR DRUG DELIVERY; ORAL ROUTE; TRANSDERMAL;

AMINO ACIDS; ANTIVIRAL AGENTS; DENDRIMERS; DRUG DELIVERY; DRUG PRODUCTS;

FUNCTIONAL POLYMERS;

BORON; CAMPTOTHECIN; CARTEOLOL; CISPLATIN; DENDRIMER; DIFLUNISAL; DOCETAXEL; DOXORUBICIN; FIRTECAN; FLUOCINOLONE; FLUOROURACIL; FLURBIPROFEN; GADOLINIUM; GLUCOSAMINE; INDIUM 111; INDOMETACIN; INSULIN; KETOPROFEN; MESALAZINE; METHOTREXATE; NANOMATERIAL; PHOSPHORUS; PILOCARPINE; PORPHYRIN; PRIMAQUINE; PROPRANOLOL; RIBOFLAVIN; TAMSULOSIN; TROPICAMIDE; UNINDEXED DRUG;

ARTHRITIS; BRAIN CANCER; CHEMICAL STRUCTURE; CLINICAL EFFECTIVENESS; CONTROLLED DRUG RELEASE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; HUMAN; HYPERTENSION; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NANOANALYSIS; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN PENETRATION; SKIN PERMEABILITY; SURFACE PROPERTY; TREATMENT OUTCOME;

DENDRIMERS; INHALATION ADMINISTRATION; INTRAVENOUS ROUTE; NASAL ADMINISTRATION; OCULAR DRUG DELIVERY; ORAL ROUTE; ROUTES OF ADMINISTRATION; TRANSDERMAL DIFFUSION;

ANIMALS; DENDRIMERS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 84885386826     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.01.001     Document Type: Review

References (157)

1. Committee on Drugs Alternative routes of drug administration - advantages and disadvantages. Pediatrics 1997, 100:143-152. (and references cited therein).
2. Available at:, (Accessed on November 2012). http://www.network-ed.com.au/pdf/samples/9780443103315_sample.pdf.
3. Philip Jevon P. Chapter 12. Miscellaneous routes of medication administration, medicines management 2010, Wiley-HC.
4. Chugh I., Seth N., Rana A.C., Gupta S. Oral sustained release drug delivery system: an overview. Int. Res. J. Pharm. 2012, 3:57-61.
5. Freitas R.A. What is nanomedicine?. Nanomed. Nanotechnol. Biol. Med. 2005, 1:2-9. (and references cited therein).
6. Caruthers S.D., Wickline S.A., Lanza G.M. Nanotechnological applications in medicine. Curr. Opin. Biotechnol. 2007, 18:26-30. (and references cited therein).
7. Ogier J., Arnauld T., Doris E. Recent advances in the field of nanometric drug carriers. Futur. Med. Chem. 2009, 1:693-711. (and references cited therein).
8. Duncan R., Gaspar R. Nanomedicine(s) under the microscope. Mol. Pharm. 2011, 8:2101-2141. (and references cited therein).
9. Wolf L.K. Personalizing nanomedicine. C&EN September 26 2011, 29-32.
10. Singh A.K., Hahn M.A., Gutwein L.G., Rule M.C., Knapik J.A., Moudgil B.M., Grobmyer S.R., Brown S.C. Multi-dye theranostic nanoparticle platform for bioimaging and cancer therapy. Int. J. Nanomedicine 2012, 7:2739-2750. (and references cited therein).
11. Gubbins P.O., Anaissie E. Overview of antifungal agents. Pharm. Pract. News Spec. Ed. 2006, 59-64.
12. Tardi P.G., Bomam N.L., Cullis P.R. Liposomal doxorubicin. J. Drug Target. 1996, 4:129-140.
13. Khandare J., Calderon M., Dagia N.M., Haag R. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem. Soc. Rev. 2012, 41:2824-2848. (and references cited therein).
14. Green M.R., Manikhas G.M., Orlov S., Afanasyev B., Makhson A.M., Bhar P., Hawkins M.J. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2006, 14:1263-1268.
15. Harris J.M., Chess R.B. The dawning era of polymer therapeutics. Rev. Drug Discov. 2003, 2:214-221.
16. Available at, (Accessed on November 2012). http://www.starpharma.com/vivagel.
17. McCarthy T.D., Karellas P., Henderson S.A., Giannis M., O'Keefe D.F., Heery G., Paull J.R.A., Matthews B.R., Holan G. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2005, 2:312318.
18. Gajbhiye V., Palanirajan V.K., Tekade R., Jain N.K. Dendrimers as therapeutic agents: a systematic review. J. Pharm. Pharmacol. 2009, 61:989-1003.
19. Gupta S., Tyagi R., Parmar V.S., Sharma S.K., Haag R. Polyether based amphiphiles for delivery of active compounds. Polymer 2012, 53:3053-3078. (and references cited therein).
20. Mintzer M.A., Grinstaff M.W. Biomedical applications of dendrimers: a tutorial. Chem. Soc. Rev. 2010, 40:173-190.
21. Astruc D., Boisselier E., Omelas C. Dendrimers designed for functions: from physical, photophysical, and supramolecular properties to applications in sensing, catalysis, molecular electronics, photonics and nanomedicine. Chem. Soc. Rev. 2010, 110:1857-1959.
22. Menjoge A.R., Kannan R.M., Tomalia D.A. Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. Drug Discov. Today 2010, 15:171-185.
23. El Kazzouli S., Mignani S., Bousmina M., Majoral J.-P. Dendrimer therapeutics: covalent and ionic attachments. New J. Chem. 2012, 36:227-240.
24. Wolinsky J.B., Mark W., Grinstaff M. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv. Drug Deliv. Rev. 2008, 60:1037-1055.
25. Tekade R.K., Kumar P.V., Jain N.K. dendrimers in oncology: an expanding horizon. Chem. Soc. Rev. 2009, 109:49-87. (and references cited therein).
26. S. Mignani, S. El Kazzouli, M. Bousmina, J.-P. Majoral, Dendrimer space concept for innovative nanomedicine: a futuristic vision in medicinal chemistry, Progress in Polymer Science, in press.
27. Anajwala C.C., Jani G.K., Swamy S.M.V. Current trends of nanotechnology for cancer therapy. Int. J. Pharm. Sci. Nanotechnol. 2010, 3:1043-1056.
28. Farokhzad O.C., Langer R. Impact of nanotechnology on drug delivery. ACSNano 2009, 3:16-20.
29. Tomalia D.A., Reyna L.A., Svenson S. Biochem. Soc. Trans. 2007, 35:61-67.
30. Jain N.K., Gupta U. Application of dendrimer-drug complexation in the enhancement of drug solubility and bioavailability. Expert. Opin. Drug Discov. 2008, 4:1035-1051.
31. Kaminskas L.M., McLeod V.M., Porter C.J.H., Boyd B.J. Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. Mol. Pharm. 2012, 9:355-373. (and references cited therein).
32. Caminade A.-M., Turrin C.O., Majoral J.-P. Biological properties of phosphorus dendrimers. New J. Chem. 2010, 34:1512-1524.
33. Kojima C. Design of stimuli-responsive dendrimers. Expert. Opin. Drug Discov. 2010, 7:307-319.
34. Ramireddy R.R., Raghupathi K.R., Torres D.A., Thayumanavan S. Stimuli sensitive amphiphilic dendrimers. New J. Chem. 2012, 36:340-349.
35. Avital-Shmilovici M., Shabat D. Self-immolative dendrimers: a distinctive approach to molecular amplification. Soft Matter 2010, 6:1073-1080. (and references cited therein).
36. Wijagkanalan W., Kawakami S., Hashida M. Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations. Pharm. Res. 2011, 28:1500-1519.
37. Lee C.C., MacKay J.A., Fréchet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat. Biol. 2005, 23:1517-1526.
38. Kaminska L.M., McLeod V.M., Porter C.J.H., Boyd B.J. Association of chemotherapeutic drugs with dendrimer nanocarriers: an assessment of the merits of covalent conjugation compared to noncovalent encapsulation. Mol. Pharm. 2012, 9:355-373. (and references cited therein).
39. Fleige E., Quadir M.A., Haag R. Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv. Drug Deliv. Rev. 2012, 64:866-884.
40. Fasting C., Schalley C.A., Weber M., Seltz O., Hecht S., Koksch B., Demedde J., Graf C., Knapp E.-W., Haag R. Multivalency as a chemical organization and action principle. Angew. Chem. Int. Ed. 2012, 51:10472-10498.
41. Malhotra S., Bauer H., Tschiche A., Staedtler A.M., Mohr A., Calderon M., Parma V.S., Hoeke L., Sharbati S., Einspanier R., Haag R. Glycine-terminated dendritic amphiphiles for nonviral gene delivery. Biomacromolecules 2012, 13:3087-3098.
42. Banard A., Posocco P., Pricl S., Calderon M., Haag R., Hwang M.E., Shum V.W.T., Pack D.W., Smith D.K. Degradable self-assembling dendrons for gene delivery: experimental and theoritical insights into barriers to cellular uptake. J. Am. Chem. Soc. 2011, 133:20288-20300.
43. Narayan P.S., Pooja S., Khushboo A., Diwakar T., Ankit S., Singhai A.K. Dendrimers as a novel drug delivery system Nov. 2010, 382-388. (www.ijplsjournal.com).
44. Ina M. Dendrimer a - a novel drug delivery system. J. Drug Deliv. Syst. 2011, 1:70-74.
45. Haag R., Kratz F. Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. 2006, 45:1198-1215.
46. Satchi-Fainaro R., Duncan R., Barnes C.M. Polymer therapeutics for cancer: current status and future challenges. Adv. Polym. Sci. 2006, 193:1-65. (and references cited therein).
47. Lammers T., Ulbrich K. HPMA copolymers: 30years of advances. Adv. Drug Deliv. Rev. 2010, 62:119-121.
48. Gaikwad D., Dhawale S., Khandare J., Patil M., KHade T., Gavitre B., Bobe K., Kulkarni V., Gaikwad U. Polymer-drug conjugates: recent achievements. Res. J. Pharm. Biol. Chem. Sci. 2011, 2:200-208.
49. Duncan R., Vicent M.J. Do HPMA copolymer conjugates have a future as clinically useful nanomedicines? A critical overview of current status and future opportunities. Adv. Drug Deliv. Rev. 2010, 62:272-282. (and references cited therein).
50. J.Kopeček, Kopečková P. HPMA copolymers: origins, early developments, present, and future. Adv. Drug Deliv. Rev. 2010, 62:122-149. (and references cited therein).
51. Liu X.-M., Miller S.C., Wang D. Beyond oncology - application of HPMA copolymers in non-cancerous diseases. Adv. Drug Deliv. Rev. 2010, 62:258-271. (and references cited therein).
52. Pike D.B., Ghandehari H. HPMA copolymer-cyclic RGD conjugates for tumor targeting. Adv. Drug Deliv. Rev. 2010, 62:167-183. (and references cited therein).
53. Katzung B.G. Basic and Clinical Pharmacology 1998, Stamford, Connecticut. Appleton & Lange (Ed.).
54. Cheng Y., Xu Z., Ma M., Xu T. Dendrimers as drug carriers: applications in different routes administration. J. Pharm. Sci. 2008, 97:123-143.
55. Malik N., Evagorou E.G., Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999, 10:767-776.
56. Kukowska-Latallo J.F., Candido K.A., Cao Z.Y., Nigavekar S.S., Majoros I.J., Thomas T.P., Balogh L.P., Khan M.K., Baker J.R. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005, 65:5317-5532.
57. van Haandel L., Stobaugh J.F. Bioanalytical method development for a generation 5 polyamidoamine folic acid methotrexate conjugated nanoparticle. Anal. Bioanal. Chem. 2010, 397:1841-1852.
58. Jiang Y.-Y., Tang G.-T., Zhang L.H., Kong S.-Y., Zhu S.-J., Pei Y.-Y. PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. J. Drug Target. 2010, 18:389-403.
59. Singh P., Gupta U., Asthana A., Jain N.K. Folate and folate-PEG-PAMAM Dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug. Chem. 2008, 11:2239-2252.
60. Kurmi B.D., Gajbhiye V., Kayat J., Jain N.K. Lactoferrin-conjugated dendritic nanoconstructs for lung targeting of methotrexate. J. Pharm. Sci. 2011, 100:2311-2320.
61. Yang W.L., Barth R.F., Adams D.M., Soloway A.H. Intratumoral delivery of boronated epidermal growth factor for neutron capture therapy of brain tumors. Cancer Res. 1997, 57:4333-4339.
62. Yang W.L., Barth R.F., Wu G., Bandyopadhya A.K., Thirumamagal B.T.S., Tjarks W., Binns P.J., Riley K., Patel H., Codere J.A. Boronated epidermal growth factor as a delivery agent for neutron capture therapy of EGF receptor positive gliomas. Appl. Radiat. Isot. 2004, 61:981-985.
63. Barth R.F., Adams D.M., Soloway A.H., Alam F., Darby M.V. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug. Chem. 1994, 5:58-66.
64. Yang W.L., Barth R.F., Adams D.M., Ciessielski M.J., Fenstermaker R.A., Shukla S., Tjarks W., Caligiuri M.A. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas. Cancer Res. 2002, 62:6552-6558.
65. Bhadra D., Bhara S., Jain N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 2003, 257:111-124.
66. Lee C.C., Gillies E.R., Fox M.E., Guilaudeu S.J., Fréchet J.M., Dy E.E., Szoka F.C. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. PNAS 2006, 7:16649-16654.
67. Gillies E.R., Dy E., Fréchet J.M., Szoka F.C. Biological evaluation of polyester dendrimer: poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. Mol. Pharm. 2005, 2:129-138.
68. Kaminskas L.M., Kelly D.B., McLeod V.M., Sberna G., Owen D.J., Boyd B.J., Porter C.J.H. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. J. Control. Release 2011, 152:241-248.
69. Fox M.E., Guillaudeu S., Fréchet J.M.J., Jerger K., Macaraeg N., Szoka F.C. Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates. Mol. Pharm. 2009, 6:1562-1572.
70. Asthana A., Chauhan A.S., Diwan P.V., Jain N.K. Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. AAPS PharmSciTech 2005, 6:E536-E542.
71. Chauhana A.S., Jain N.K., Diwana P.V., Khopadec A.J. Solubility enhancement of indomethacin with poly(amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J. Drug Target. 2004, 12:575-583.
72. Bhadra D., Yadav A.K., Bhadra S., Jain N.K. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int. J. Pharm. 2005, 295:221-233.
73. Kukowska-Latallo J.F., Chen C., Raczka E., Qunintana A., Rymaszewski M., Baker J.R. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Hum. Gene Ther. 2000, 11:1385-1395.
74. Kihara F., Arima H., Tsutsumi T., Hirayama F., Uekama K. In vitro and in vivo gene transfer by an optimized alpha-cyclodextrin conjugate with polyamidoamine dendrimer. Bioconjug. Chem. 2003, 14:342-350.
75. Wada K.H., Arima H., Tsutsumi T., Chihara Y., Hattori K., Hirayama F., Uekama K. Improvement of gene delivery mediated by mannosylated dendrimer/α-cyclodextrin conjugates. J. Control. Release 2005, 104:397-413.
76. Dufes C., Keith W.N., Bilsland A., Proutski I., Uchegbu I.F., Schatzlein A.G. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res. 2005, 65:8079-8084.
77. Tack F., Bakker A., Maes S., Dekeyser N., Bruining M., Elissen-Roman C., Janicot M., Brewster M., Janssen H.M., Waal B.F.M., Fransen P.M., Lou X., Meijer E.W. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J. Drug Target. 2006, 14:69-86.
78. Boswell C.A., Eck P.K., Regino C.A.S., Bernardo M., Wrong K.J., Milenic D.E., Choyke P.L., Brechbiel M.W. Synthesis, characterization, and biological evaluation of integrin αvβ3-targeted PAMAM dendrimers. Mol. Pharm. 2008, 5:527-539.
79. Floyd W.C., Datta G.K., Imamura S., Kieler-Ferguson H.M., Jerger K., Patterson A.W., Fox M.E., Szoka F.C., Fréchet J.M.J., Ellman J.A. Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in C26 tumor bearing mice. ChemMedChem 2011, 6:49-53.
80. Gajbhiye V., Jain N.K. The treatment of glioblastoma xenografts by surfactant conjugated dendritic nanoconjugates. Biomaterials 2011, 32:6213-6225.
81. Vincent L., Varet J., Pille J.Y., Bompais H., Opolon P., Maksimenko A., Malvy C., Mirshahi M., Lu H., Soria J.P.V.C., Li H. Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studies. Int. J. Cancer 2003, 105:419-429.
82. Wu G., Barth R.F., Yang W.L., Chatterjee M., Tjarks W., Ciesielski M.J., Fenstermaker R.A. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug. Chem. 2004, 15:185-194.
83. Barth R.F., Adams D.M., Soloway A.H., Alam F., Darby M.V. Boronated starburst dendrimer-monoclonal antibody immunoconjugates: evaluation as a potential delivery system for neutron capture therapy. Bioconjug. Chem. 1994, 5:58-66.
84. Vannucci L., Fiserova A., Sadalapure K., Lindhorst T.K., Kuldova M., Rossmann P., Horvath O., Kren V., Krist P., Bezouska K., Luptovcova M., Mosca F., Pospisil M. Effects of N-acetyl-glucosamine-coated glycodendrimers as biological modulators in the B16F10 melanoma model in vivo. Int. J. Oncol. 2003, 23:285-296.
85. Di Venosa G., Casas A., Battah S., Dobbin P., Fukuda H., Macrobert A., Battle A. Investigation of a novel dendritic derivative of 5-aminolaevulinic acid for photodynamic therapy. Int. J. Biochem. Cell Biol. 2006, 38:82-91.
86. Sato N., Kobayashi H., Saga T., Nakamoto Y., Ishimori T., Togashi K., Fujibayashi Y., Konishi J., Brechbiel M.W. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin. Cancer Res. 2001, 7:3606-3612.
87. Mamede M., Saga T., Kobayashi H., Ishimori T., Higashi T., Sato N., Brechbiel M.W., Konishi J. Radiolabeling of avidin with very high specific activity for internal radiation therapy of intraperitoneally disseminated tumors. Clin. Cancer Res. 2003, 9:3756-3762.
88. Chauhan A.S., Jain N.K., Diwan P.V. Pre-clinical and behavioural toxicity profile of PAMAM dendrimers in mice. Proc. R. Soc. A 2009, 3. 10.1098/rspa.2009.0448.
89. Kuno N., Fujii S. Recent advances in ocular drug delivery systems. Polymers 2011, 3:193-221.
90. Khar R.K., Jain G.K., Warsi M.H., Mallick N.M., Akhter S., Pathan S.A., Ahmad F.J. Nano-vectors for ocular delivery of nucleic acid-based therapeutics. Indian J. Pharm. Sci. 2010, 72:675-688.
91. Thakur R.R., Kashiv M. Modern delivery systems for ocular drug formulations: a comparative overview W.R.T. conventional dosage form. Intl. J. Biomed. Pharma. Sci. 2011, 2:8-18.
92. Amrite A.C., Kompella U.B. Nanoparticles for ocular drug delivery. Nanoparticle Technology for Drug Delivery 2006, Taylor & Francis, (and references cited therein). R.B. Gupta, U.B. Kompella (Eds.).
93. Wadhwa S., Paliwal R., Paliwal S.R., Vyas S.P. Nanocarriers in ocular drug delivery: an update review. Curr. Pharm. Des. 2009, 15:2724-2750. (and references cited therein).
94. Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv. Drug Deliv. Rev. 2008, 60:1663-1673. (and references cited therein).
95. Vandamme Th.F., Brobeck L. Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. J. Control. Release 2005, 102:23-38.
96. Shaunak S., Thomas S., Gianasi E., Godwin A., Jones E., Teo I., Mireskandari K., Luthert P., Duncan R., Patterson S., Khaw P., Brocchini S. Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol. 2004, 22:977-984.
97. Duan X., Sheardown H. Dendrimer crosslinked collagen as a corneal tissue engineering scaffold: mechanical properties and corneal epithelial cell interactions. Biomaterials 2006, 27:4608-4617.
98. Spataro G., Malecaze F., Turrin C.-O., Soler V., Duhayon C., Elena P.-P., Majoral J.-P., Caminade A.-M. Designing dendrimers for ocular drug delivery. Eur. J. Med. Chem. 2010, 45:326-334.
99. Iezzi R., Guru B.R., Glybina I.V., Mishra M.K., Kennedy A., Kannan R.M. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012, 33:979-988.
100. Marano R.J., Wimmer N., Kearns P.S.b, Thomas B.G., Toth I., Brankova M., Rakoczy P.E. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp. Eye Res. 2004, 79:525-535.
101. Naik A., Kalia Y.N., Guy R.H. Transdermal drug delivery: overcoming the skin-barrier function. Pharm. Sci. Technol. Today 2000, 3:318326.
102. Prausnitz M.R., Langer R. Transdermal drug delivery. Nat. Biotechnol. 2008, 26:1261-1268.
103. Thomas B.J., Finnin B.C. The transdermal revolution. Drug Discov. Today 2004, 9:697703.
104. Tolia G.T., Choi H.H. The role of dendrimers in topical drug delivery. Pharm. Technol. 2008, 32:88-98. (and references cited therein).
105. Ramachandran C., Fleisher R.D. Transdermal delivery of drugs for the treatment of bone diseases. Adv. Drug Deliv. Rev. 2000, 42:197-223.
106. Holana V., Chudickova M., Trosan P., Svobodova E., Krulova M., Kubinova S., Sykova E., Sirc J., Michalek J., Juklickova M., Munzarova M., Zajicova A. Cyclosporine A-loaded and stem cell-seeded electrospun nanofibers for cell-based therapy and local immunosuppression. J. Control. Release 2011, 156:406-412.
107. Shembale A.I., Borole D.K., Lohiya R.T. Useful permeation enhancers for transdermal drug delivery: a review. Int. J. Pharm. Res. Dev. 2012, 2:1-6. For representative examples, see:.
108. Pathan I.B., Setty C.M. Chemical penetration enhancers for transdermal drug delivery systems. Trop. J. Pharm. Res. 2009, 8:173-179.
109. Karande P., Jain A., Ergun K., Kispersky V., Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery. PNAS 2005, 102:4688-4693.
110. Santander-Ortega M.J., Stauner T., Loretz B., Ortega-Vinuesa J.L., Bastos-Gonzalez D., Wenz G., Schaefer U.F., Lehr C.M. Nanoparticles made from novel starch derivatives for transdermal drug delivery. J. Control. Release 2010, 141:85-92.
111. Sun M., Fan A., Wang Z., Zhao Y. Dendrimer-mediated drug delivery to the skin. Soft Matter 2012, 8:4301-4305.
112. Venuganti V.V.K., Perumal O.P. Poly(amidoamine) dendrimers as skin penetration enhancers: influence of charge, generation and concentration. J. Pharm. Sci. 2009, 98:2345-2356.
113. Venuganti V.V.K., Sahdev P., Hildreth M., Guan X., Perumal O. Structure-skin permeability relationship of dendrimers. Pharm. Res. 2011, 28:2246-2260.
114. Yang Y., Sunoqrot S., Stowell C., Ji J., Lee C.-W., Kim J.W., Khan S.A., Hong S. The effect of size, surface charge and hydrophobicity of poly(amidoamine) dendrimers on their skin penetration. Biomacromelecules 2012, 13:2154-2162.
115. Venuganti V.V.K., Perumal O.P. Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of 5-fluorouracil. Int. J. Pharm. 2008, 361:230-238.
116. Wiwattanapatapee R., Carreno-Gomez B., Malik N., Duncan R. Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system?. Pharm. Res. 2000, 17:991-998.
117. Jevprasesphant R., Penny J., Attwood D., D'Emanuele A. Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J. Control. Release 2004, 97:259-267.
118. Wang Z., Ito Y., Hosaka Y., Kobayashi I., Nakano Y., Maeda I., Umeda F., Yamakawa J., Kawase M., Yagi K. Novel transdermal drug delivery system with polyhydroxyalkanoate and Starburst polyamidoamine dendrimer. J. Biosci. Bioeng. 2003, 95:541-543.
119. Wang Z., Itoh Y., Hosaka Y., Kobayashi I., Nakano Y., Maeda I., Umeda F., Yamakawa J., Nishimine M., Suenobu T., Fukuzumi S., Kawase M., Yagi K. Mechanism of enhancement effect of dendrimer on transdermal drug permeation through polyhydroxyalkanoate matrix. J. Biosci. Bioeng. 2003, 95:537-540.
120. Kim H., Choi H.K. Effect of additives on the crystallization and the permeation of ketoprofen from adhesive matrix. Int. J. Pharm. 2002, 236:81-85.
121. Wang Z., Itoh Y., Hosaka Y., Kobayashi I., Nakano Y., Maeda I., Umeda F., Yamakawa J., Kawase M., Yagi K. J. Biosci. Bioeng. 2003, 95:541-543.
122. Bielinska A.U., Yen A., Wu H.L., Zahos K.M., Sun R., Weiner N.D., Baker J.R., Roesslezer B.J. Application of membrane-based dendrimer/DNA complexes for solid phase transfection in vitro and in vivo. Biomaterials 2000, 21:877-887.
123. Chauban A.S., Sridevi S., Chalasani K.B., Jain A.K., Jain S.K., Jain N.K., Diwan P.V. Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. J. Control. Release 2003, 90:335-343.
124. Cheng Y., Man N., Xu T., Fu R., Wang X., Wang X., Wen L. Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J. Pharm. Sci. 2007, 96:595-602.
125. Hörl W.H. Nonsteroidal anti-inflammatory drugs (NSAIDs) and the kidney. Pharmaceuticals 2010, 3:2291-2321.
126. Borowska K., Laskowska B., Magon A., Mysliwiec, Pyda M., Wolowiec S. PAMAM dendrimers as solubilizers and hosts for 8-methoxypsoralene enabling transdermal diffusion guest. Int. J. Pharm. 2010, 398:185-189.
127. Filipowicz A., Wolowiec S. Solubility and in vitro transdermal diffusion of riboflavin assisted by PAMAM dendrimers. Int. J. Pharm. 2011, 408:152-156.
128. Moghimi H.R., Varshochian R., Kobarfard F., Erfan M. Reduction of percutaneous absorption of toxic chemicals by dendrimers. Cutan. Ocul. Toxicol. 2010, 29:34-40.
129. Küchler S., Radowski M.R., Blaschke T., Dathe M., Plendl J., Haag R., Schäfer-Korting M., Kramer K.D. Nanoparticles for skin penetration enhancement - a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur. J. Pharm. 2009, 71:243-250.
130. Hillery A., Lloyd A.W., Swarbrick J. Drug Delivery and Targeting 2001, (London and New York, and references cited therein). Taylor & Francis (Ed.).
131. Kojima C., Kono K., Maruyama K., Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate 2000, 11:910-917.
132. Lambkin I., Pinilla C. Targeting approaches to oral drug delivery. Expert. Opin. Biol. Ther. 2002, 2:67-73.
133. Sadekar S., Ghandehari H. Transepithelial transport and toxicity of PAMAM dendrimers: implications for oral drug delivery. Adv. Drug Deliv. Rev. 2012, 64:571-588. For very interesting review/article, see:.
134. Duncan R., Spreafico F. Polymer conjugates. Pharmacokinetic considerations for design and development. Clin. Pharmacokinet. 1994, 27:290-306.
135. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701. (and references cited therein).
136. Sakthivel T., Toth I., Florence A.T. Distribution of a lipidic 2.5nm diameter dendrimer carrier after oral administration. Int. J. Pharm. 1999, 183:51-55.
137. D'Emanuele A., Jevprasesphant R., Penny J., Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J. Control. Release 2004, 95:447-453.
138. Florence A.T., Sakthivel T., Toth I. Oral uptake and translocation of a polylysine dendrimer with a lipid surface. J. Control. Release 2000, 65:253-259.
139. Tripathi P.K., Khopade A.J., Nagaich S., Shrivastava S., Jain S., Jain N.K. Dendrimer grafts for delivery of 5-fluorouracil. Pharmazie 2002, 57:261-264.
140. Wiwattanapatapee R., Lomlim L., Saramunee K. Dendrimers conjugates for colonic delivery of 5-aminosalicylic acid. J. Control. Release 2003, 88:1-9.
141. Na M., Yiyun C., Tongwen X., Yang D., Xiaomin W., Zhenwei L., Zhichao C., Guanyi H., Yunyu S., Longping W. Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vivo and in vitro studies. Eur. J. Med. Chem. 2006, 41:670-674.
142. Kolhatkar R.B., Swaan P., Ghandehari H. Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers. Pharm. Res. 2008, 25:1723-1729.
143. Lin Y., Fujimari T., Kawaguchi N., Tsujimoto Y., Nishimi M., Dong Z., Katsumi H., Sakane T., Yamamoto A. Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats. J. Control. Release 2011, 149:21-28.
144. Tajarobi F., El-Sayed M., Rege B.D., Polli J.E., Ghandehari H. Transport of poly amidoamine dendrimers across Madin-Darby canine kidney cells. Int. J. Pharm. 2001, 215:263-267.
145. Hong S., Bielinska A.U., Mecke A., Beals J.L., Shi X., Orr L.B.G., Baker J.R., Holl M.M.B. Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug. Chem. 2004, 15:774-782.
146. El-Sayed M., Rhodes C.A., Ginski M., Ghandehari H. Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int. J. Pharm. 2003, 265:151-157.
147. Jevprasesphant J., Penny J., Attwood D., McKeown N.B., D'Emanuele A. Engineering of dendrimer surfaces to enhance transepithelial transport and reduce cytotoxicity. Pharm. Res. 2003, 20:1543-1550.
148. Menjoge A.R., Navath R.S., Asad A., Kannan S., Kim C.J., Romero R., Kannan R.M. Transport and biodistribution of dendrimers across human fetal membranes: implications for intravaginal administration of dendrimer-drug conjugates. Biomaterials 2010, 31:5007-5021.
149. Seabrook T.J., Jiang L., Thomas K., Lemere C.A. Boosting with intranasal dendrimeric Aβ1-15 but not Aβ1-15 peptide leads to an effective immune response following a single injection of Aβ1-40/42 in APP-tg mice. J. Neuroinflammation 2006, 3:1-10.
150. Dong Z., Katsumi H., Sakane T., Yamamoto A. Effects of polyamidoamine (PAMAM) dendrimers on the nasal absorption of poorly absorbable drugs in rats. Int. J. Pharm. 2010, 30:244-252.
151. Inapagolla R., Guru B.R., Kurtoglu Y.E., Gao X., L.ieh-Lai M., Bassett D.J.P., Kannan R.M. In vivo efficacy of dendrimer-methylprednisolone conjugate formation for the treatment of lung inflammation. Int. J. Pharm. 2010, 339:140-147.
152. Dong Z., Hamid K.A., Gao Y., Lin Y., Katsumi H., Sakane T., Yamamoto A. Polyamidoamine dendrimers can improve the pulmonary absorption of insulin and calcitonin in rats. J. Pharm. Sci. 2011, 100:1866-1878.
153. Bai S., Thomas C., Ahsan F. Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. J. Pharm. Sci. 2007, 96:2090-2106.
154. Carvalho T.C., Peters J.I., Ill R.O.W. Influence of particle size on regional lung deposition - what evidence is there?. Int. J. Pharm. 2011, 406:1-10.
155. Choi H.S., Ashitate Y., Lee J.H., Kim S.H., Matsui A., Insin N., Bawendi M.G., Semmler-Behnke M., Frangioni J., Tsuda A. Rapid translocation of nanoparticles from lung airspaces to the body. Nat. Biotechnol. 2010, 28:1300-1304.
156. Lam J.K.-W., Liang W., Chan H.-K. Adv. Drug Deliv. Rev. 2012, 64:1-15.
157. Anderson G.D., Saneto R.P. Current oral and non-oral routes of antiepileptic drug delivery. Adv. Drug Deliv. Rev. 2012, 64:911-918.